CN109289043A - A kind of pharmaceutical composition for treating cerebral infarction - Google Patents

A kind of pharmaceutical composition for treating cerebral infarction Download PDF

Info

Publication number
CN109289043A
CN109289043A CN201811324080.0A CN201811324080A CN109289043A CN 109289043 A CN109289043 A CN 109289043A CN 201811324080 A CN201811324080 A CN 201811324080A CN 109289043 A CN109289043 A CN 109289043A
Authority
CN
China
Prior art keywords
pharmaceutical composition
cerebral infarction
powder
filtrate
portulaca oleracea
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201811324080.0A
Other languages
Chinese (zh)
Inventor
韦玉
韦一玉
李长润
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ANHUI PROVINCE SCIENCE TECHNOLOGY RESEARCH INSTITUTE
Original Assignee
ANHUI PROVINCE SCIENCE TECHNOLOGY RESEARCH INSTITUTE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ANHUI PROVINCE SCIENCE TECHNOLOGY RESEARCH INSTITUTE filed Critical ANHUI PROVINCE SCIENCE TECHNOLOGY RESEARCH INSTITUTE
Priority to CN201811324080.0A priority Critical patent/CN109289043A/en
Publication of CN109289043A publication Critical patent/CN109289043A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/41—Crassulaceae (Stonecrop family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/80—Scrophulariaceae (Figwort family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21062—Subtilisin (3.4.21.62)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention belongs to drug field more particularly to a kind of pharmaceutical compositions for treating cerebral infarction.Pharmaceutical composition of the present invention is preferred tablet, capsule, pill, granule, powder and suspension made of false portulaca oleracea extracts, Distylium racemosum leaf extract, Kalanchoe Tomentosa powder, citicoline, Nattokinase, vinpocetine.Pharmacodynamic experiment confirms; pharmaceutical composition of the present invention has preferable therapeutic effect to cerebral infarction convalescence; and this composition prescription is simple, easy to control the quality, good security, treatment cost are lower, is suitable for all types of cerebral infarction patients, is very suitable to current clinical demand.

Description

A kind of pharmaceutical composition for treating cerebral infarction
Technical field
The invention belongs to drug field more particularly to a kind of pharmaceutical compositions for treating cerebral infarction.
Background technique
Cerebral infarction, also known as ischemia apoplexy or cerebral arterial thrombosis (cerebral ischemic stroke), refer to because Brain blood supplies obstacle, and the necrosis of limitation brain tissue ischemia or softening caused by ischemic, anoxic, clinical manifestation is with sudden It so faints, is senseless, hemiplegia, disfluency, dysnoesia are main feature.The clinical common type of cerebral infarction has brain blood Bolt formation, lacunar infarction and cerebral embolism etc., cerebral infarction accounts for the 80% of whole cerebral apoplexies, not only causes greatly to human life and health It threatens, and brings greatly pain and heavy burden to patient, family and society.
It mainly include two aspects of diuretic therapy and thromboembolism treatment about the drug therapy of cerebral infarction acute stage and convalescence, Diuretic therapy mostly uses dehydrating agent mannitol, Glycerin Fructose, frusemide etc. and cortex hormone of aadrenaline and human serum albumin；It is molten Bolt treatment mostly uses streptokinase, urokinase, Lumbrokinase and anti-coagulant heparin, warfarin etc..However, said medicine was using Higher risk is all had in journey, if diuretics easily leads to de- water and rock-soil coupling, there is also drug withdrawal rebound phenomenon；On kidney The adverse reaction of gland cortin is more and serious；Human serum albumin can cause dehydration, body circulation excess load, congestive heart failure And pulmonary edema；Kinases drug easily leads to bleeding and allergy；Anti-coagulants improper use easily causes bleeding, aggravates the state of an illness.In addition to upper It states except drug, there are also compound Chinese medicinal preparations to be used for cerebral infarction convalescent care at present, but works relatively slow and curative effect mostly simultaneously It is not significant, and this kind of compound Chinese medicinal preparation often complicated composition, producting process difficulty is big, can not only control to the quality of product It creates great difficulties, and is unfavorable for keeping the stability of product quality, in addition, taking Chinese medicine needs diagnosis and treatment based on an overall analysis of the illness and the patient's condition, arbitrarily take With ineffective or even the state of an illness can be aggravated.
To sum up, the intrinsic defect of existing cerebral infarction therapeutic agent largely reduces the tolerance and compliance of patient Property.
Summary of the invention
The present invention is intended to provide a kind of pharmaceutical composition for treating cerebral infarction, pharmaceutical composition of the present invention forms simple, curative effect Definitely, good security and treatment cost is lower.
The pharmaceutical composition that the present invention treats cerebral infarction is made of the raw material of following weight parts:
False portulaca oleracea extracts 300-450, Distylium racemosum leaf extract 300-325,
Kalanchoe Tomentosa powder 120-130, citicoline 470-510,
Nattokinase 90-105, vinpocetine 9-12.
Further, the false portulaca oleracea extracts in this pharmaceutical composition raw material are made by the following method: by false dent 8-10 times, which is added, after amaranth rinsing, dry, crushing measures 30% ethyl alcohol, refluxing extraction 1 hour after impregnating 2 hours, medical fluid filtration, filtrate It is spare, under the same conditions filter residue is repeated to extract 1 time, filtering, merging filtrate is spray-dried after being concentrated under reduced pressure into small size, Obtain false portulaca oleracea extracts.
Further, the Distylium racemosum leaf extract in this pharmaceutical composition raw material is made by the following method: by Distylium racemosum 5 times of amount petroleum ethers are added after being crushed to 200 mesh in leaf rinsing, drying, are filtered by vacuum after impregnating 2 hours, filtrate are discarded, to filter residue Yi Chun ﹕ ethyl acetate=7 ﹕, 3 mixed solution is measured in middle 8-10 times of addition, refluxing extraction 1 hour after impregnating 1 hour, medical fluid filtration, and filter Liquid is spare, repeats to extract 1 time by filter residue under the same conditions, and filtering merges filtrate twice, is concentrated under reduced pressure into after small size by spraying It is dry, obtain Distylium racemosum leaf extract.
Further, the Kalanchoe Tomentosa powder in this pharmaceutical composition raw material is made by the following method: by Kalanchoe Tomentosa leaf Piece rinsed clean, 80-90 DEG C dries, and 300-400 mesh is crossed after ultramicro grinding, obtains Kalanchoe Tomentosa powder.
Further, this pharmaceutical composition is made by following steps:
(1) 8-10 times will be added after bacopa monnieri rinsing, dry, crushing measure 30% ethyl alcohol, refluxing extraction after impregnating 2 hours 1 hour, medical fluid filtration, filtrate was spare, repeated to extract 1 time by filter residue under the same conditions, filtering, and merging filtrate is concentrated under reduced pressure It is spray-dried after to small size, obtains false portulaca oleracea extracts；
(2) Distylium racemosum leaf rinsed, is dry, being crushed to 5 times of amount petroleum ethers of addition after 200 mesh, vacuum is taken out after impregnating 2 hours Filter, discards filtrate, and 8-10 times is added into filter residue and measures Yi Chun ﹕ ethyl acetate=7 ﹕, 3 mixed solution, flows back and mentions after impregnating 1 hour It takes 1 hour, medical fluid filtration, filtrate is spare, repeats to extract 1 time by filter residue under the same conditions, and filtering merges filtrate twice, subtracts Pressure is spray-dried after being concentrated into small size, obtains Distylium racemosum leaf extract；
(3) by Kalanchoe Tomentosa blade rinsed clean, 80-90 DEG C is dried, and 300-400 mesh is crossed after ultramicro grinding, is obtained brown Spot Buddhist temple powder；
(4) above-mentioned false portulaca oleracea extracts, Distylium racemosum leaf extract, Kalanchoe Tomentosa powder and citicoline, natto are swashed Enzyme, vinpocetine mixing, mix well in blender to get this pharmaceutical composition.
The parts by weight that this pharmaceutical composition raw material is made are preferred:
False portulaca oleracea extracts 300, Distylium racemosum leaf extract 300,
Kalanchoe Tomentosa powder 120, citicoline 470,
Nattokinase 90, vinpocetine 9.
The parts by weight of above-mentioned raw materials are further preferably:
False portulaca oleracea extracts 360, Distylium racemosum leaf extract 310,
Kalanchoe Tomentosa powder 125, citicoline 500,
Nattokinase 100, vinpocetine 10.
The parts by weight of above-mentioned raw materials are further preferably:
False portulaca oleracea extracts 450, Distylium racemosum leaf extract 325,
Kalanchoe Tomentosa powder 130, citicoline 510,
Nattokinase 105, vinpocetine 12.
Further, aforementioned pharmaceutical compositions are prepared tablet, capsule, pill, granule, dissipated by this field is conventional This medicinal composition tablets, capsule, pill, granule, powder or suspension is made in the method for agent or suspension.
Moreover, it relates to the pharmaceutical composition of above-mentioned treatment cerebral infarction answering in preparation treatment cerebral apoplexy drug With.
Through testing, pharmaceutical composition of the present invention has preferable therapeutic effect, and this composition safety to cerebral infarction convalescence Property it is good, treatment cost is lower, be suitable for all types of cerebral infarction patients, be very suitable to current clinical demand.
Specific embodiment
Illustrate embodiments of the present invention below by way of specific specific example, those skilled in the art can be by this specification Other advantages and efficacy of the present invention can be easily understood for disclosed content.The present invention can also pass through in addition different specific realities The mode of applying is embodied or practiced, the various details in this specification can also based on different viewpoints and application, without departing from Various modifications or alterations are carried out under spirit of the invention.
Before further describing the specific embodiments of the present invention, it should be appreciated that protection scope of the present invention is not limited to down State specific specific embodiment；It is also understood that term used in the embodiment of the present invention is specific specific in order to describe Embodiment, rather than limiting the scope of protection of the present invention.
Unless otherwise defined, all technical and scientific terms and those skilled in the art of the present technique used in the present invention are usual The meaning of understanding is identical.In addition to specific method, equipment, material used in the embodiment, according to those skilled in the art Grasp and record of the invention to the prior art, can also use and method described in the embodiment of the present invention, equipment, material Any method, equipment and the material of the similar or equivalent prior art realizes the present invention.
The therapeutic effect of pharmaceutical composition of the present invention is described in detail below in conjunction with specific embodiment and comparative example.
Embodiment 1
A kind of pharmaceutical composition for treating cerebral infarction, this pharmaceutical composition are made of the raw material of following weight parts:
False portulaca oleracea extracts 360, Distylium racemosum leaf extract 310,
Kalanchoe Tomentosa powder 125, citicoline 500,
Nattokinase 100, vinpocetine 10.
The preparation method is as follows:
(1) 10 times of 30% ethyl alcohol of amount will be added after bacopa monnieri rinsing, dry, crushing, refluxing extraction 1 after impregnating 2 hours Hour, medical fluid filtration, filtrate is spare, repeats to extract 1 time by filter residue under the same conditions, and filtering, merging filtrate is concentrated under reduced pressure into It is spray-dried after small size, obtains false portulaca oleracea extracts；
(2) Distylium racemosum leaf rinsed, is dry, being crushed to 5 times of amount petroleum ethers of addition after 200 mesh, vacuum is taken out after impregnating 2 hours Filter, discards filtrate, and 10 times of amount Yi Chun ﹕ ethyl acetate=7 ﹕, 3 mixed solutions are added into filter residue, refluxing extraction 1 after impregnating 1 hour Hour, medical fluid filtration, filtrate is spare, repeats to extract 1 time by filter residue under the same conditions, and filtering merges filtrate twice, depressurizes dense It is spray-dried after being reduced to small size, obtains Distylium racemosum leaf extract；
(3) by Kalanchoe Tomentosa blade rinsed clean, 85 DEG C are dried, and 300 meshes are crossed after ultramicro grinding, obtain Kalanchoe Tomentosa Powder；
(4) above-mentioned false portulaca oleracea extracts, Distylium racemosum leaf extract, Kalanchoe Tomentosa powder and citicoline, natto are swashed Enzyme, vinpocetine mixing, mix well in blender to get this pharmaceutical composition.
Embodiment 2
A kind of pharmaceutical composition for treating cerebral infarction, this pharmaceutical composition are made of the raw material of following weight parts:
False portulaca oleracea extracts 300, Distylium racemosum leaf extract 300,
Kalanchoe Tomentosa powder 120, citicoline 470,
Nattokinase 90, vinpocetine 9.
The preparation method is as follows:
(1) 9 times of 30% ethyl alcohol of amount will be added after bacopa monnieri rinsing, dry, crushing, refluxing extraction 1 is small after impregnating 2 hours When, medical fluid filtration, filtrate is spare, repeats to extract 1 time by filter residue under the same conditions, and filtering, merging filtrate is concentrated under reduced pressure into small It is spray-dried after volume, obtains false portulaca oleracea extracts；
(2) Distylium racemosum leaf rinsed, is dry, being crushed to 5 times of amount petroleum ethers of addition after 200 mesh, vacuum is taken out after impregnating 2 hours Filter, discards filtrate, and 9 times of amount Yi Chun ﹕ ethyl acetate=7 ﹕, 3 mixed solutions are added into filter residue, refluxing extraction 1 after impregnating 1 hour Hour, medical fluid filtration, filtrate is spare, repeats to extract 1 time by filter residue under the same conditions, and filtering merges filtrate twice, depressurizes dense It is spray-dried after being reduced to small size, obtains Distylium racemosum leaf extract；
(3) by Kalanchoe Tomentosa blade rinsed clean, 80 DEG C are dried, and 400 meshes are crossed after ultramicro grinding, obtain Kalanchoe Tomentosa Powder；
(4) above-mentioned false portulaca oleracea extracts, Distylium racemosum leaf extract, Kalanchoe Tomentosa powder and citicoline, natto are swashed Enzyme, vinpocetine mixing, mix well in blender to get this pharmaceutical composition.
Embodiment 3
A kind of pharmaceutical composition for treating cerebral infarction, this pharmaceutical composition are made of the raw material of following weight parts:
False portulaca oleracea extracts 450, Distylium racemosum leaf extract 325,
Kalanchoe Tomentosa powder 130, citicoline 510,
Nattokinase 105, vinpocetine 12.
The preparation method is as follows:
(1) 8 times of 30% ethyl alcohol of amount will be added after bacopa monnieri rinsing, dry, crushing, refluxing extraction 1 is small after impregnating 2 hours When, medical fluid filtration, filtrate is spare, repeats to extract 1 time by filter residue under the same conditions, and filtering, merging filtrate is concentrated under reduced pressure into small It is spray-dried after volume, obtains false portulaca oleracea extracts；
(2) Distylium racemosum leaf rinsed, is dry, being crushed to 5 times of amount petroleum ethers of addition after 200 mesh, vacuum is taken out after impregnating 2 hours Filter, discards filtrate, and 8 times of amount Yi Chun ﹕ ethyl acetate=7 ﹕, 3 mixed solutions are added into filter residue, refluxing extraction 1 after impregnating 1 hour Hour, medical fluid filtration, filtrate is spare, repeats to extract 1 time by filter residue under the same conditions, and filtering merges filtrate twice, depressurizes dense It is spray-dried after being reduced to small size, obtains Distylium racemosum leaf extract；
(3) by Kalanchoe Tomentosa blade rinsed clean, 90 DEG C are dried, and 300 meshes are crossed after ultramicro grinding, obtain Kalanchoe Tomentosa Powder；
(4) above-mentioned false portulaca oleracea extracts, Distylium racemosum leaf extract, Kalanchoe Tomentosa powder and citicoline, natto are swashed Enzyme, vinpocetine mixing, mix well in blender to get this pharmaceutical composition.
Comparative example 1
A kind of pharmaceutical composition for treating cerebral infarction, this pharmaceutical composition are made of the raw material of following weight parts:
False portulaca oleracea extracts 360, citicoline 500,
Nattokinase 100, vinpocetine 10.
The preparation method is as follows:
(1) 10 times of 30% ethyl alcohol of amount will be added after bacopa monnieri rinsing, dry, crushing, refluxing extraction 1 after impregnating 2 hours Hour, medical fluid filtration, filtrate is spare, repeats to extract 1 time by filter residue under the same conditions, and filtering, merging filtrate is concentrated under reduced pressure into It is spray-dried after small size, obtains false portulaca oleracea extracts；
(2) above-mentioned false portulaca oleracea extracts and citicoline, Nattokinase, vinpocetine are mixed, in blender It mixes well to get this pharmaceutical composition.
Comparative example 2
A kind of pharmaceutical composition for treating cerebral infarction, this pharmaceutical composition are made of the raw material of following weight parts:
False portulaca oleracea extracts 360, Kalanchoe Tomentosa powder 125,
Citicoline 500, Nattokinase 100,
Vinpocetine 10.
The preparation method is as follows:
(1) 10 times of 30% ethyl alcohol of amount will be added after bacopa monnieri rinsing, dry, crushing, refluxing extraction 1 after impregnating 2 hours Hour, medical fluid filtration, filtrate is spare, repeats to extract 1 time by filter residue under the same conditions, and filtering, merging filtrate is concentrated under reduced pressure into It is spray-dried after small size, obtains false portulaca oleracea extracts；
(2) by Kalanchoe Tomentosa blade rinsed clean, 85 DEG C are dried, and 300 meshes are crossed after ultramicro grinding, obtain Kalanchoe Tomentosa Powder；
(3) above-mentioned false portulaca oleracea extracts, Kalanchoe Tomentosa powder and citicoline, Nattokinase, vinpocetine are mixed, It mixes well in blender to get this pharmaceutical composition.
Comparative example 3
A kind of pharmaceutical composition for treating cerebral infarction, this pharmaceutical composition are made of the raw material of following weight parts:
False portulaca oleracea extracts 360, Distylium racemosum leaf extract 310,
Citicoline 500, Nattokinase 100,
Vinpocetine 10.
The preparation method is as follows:
(1) 10 times of 30% ethyl alcohol of amount will be added after bacopa monnieri rinsing, dry, crushing, refluxing extraction 1 after impregnating 2 hours Hour, medical fluid filtration, filtrate is spare, repeats to extract 1 time by filter residue under the same conditions, and filtering, merging filtrate is concentrated under reduced pressure into It is spray-dried after small size, obtains false portulaca oleracea extracts；
(2) Distylium racemosum leaf rinsed, is dry, being crushed to 5 times of amount petroleum ethers of addition after 200 mesh, vacuum is taken out after impregnating 2 hours Filter, discards filtrate, and 10 times of amount Yi Chun ﹕ ethyl acetate=7 ﹕, 3 mixed solutions are added into filter residue, refluxing extraction 1 after impregnating 1 hour Hour, medical fluid filtration, filtrate is spare, repeats to extract 1 time by filter residue under the same conditions, and filtering merges filtrate twice, depressurizes dense It is spray-dried after being reduced to small size, obtains Distylium racemosum leaf extract；
(3) by above-mentioned false portulaca oleracea extracts, Distylium racemosum leaf extract and citicoline, Nattokinase, vinpocetine Mixing, mixes well in blender to get this pharmaceutical composition.
Pharmacodynamic experiment
Pharmacodynamics test is carried out to pharmaceutical composition obtained in above-described embodiment 1 and comparative example 1-3.
[experiment purpose]
Pharmaceutical composition of the present invention is observed to cerebral infarction rat model Symptoms, brain water content, Brain stem injury, blood The influence of clear SOD, MDA level.
[experimental material]
Test medicine: (be configured to concentration respectively with water is pharmaceutical composition made from embodiment 1, comparative example 1-3 The suspension of 20.0mg/ml).
Positive drug: Xueshuan xinmaining Tablet (the last suspension that concentration is configured to as 20.0mg/ml with water of pulverizing).
Experimental animal: Wistar rat, 3-4 monthly age, weight 250-300g, half male and half female.
[modeling method]
Electric heater, which is burnt, prepares Rats With Unilateral part Cerebral Infarction Model: from rat socket of the eye posterior approach by way of being burnt with electric heater Arteria cerebri media, so that blocking blood flow makes Cerebral Infarction Model completely.Specific step is as follows:
(1) anesthesia of 10% chloraldurate solution (0.33ml/100g), right lateral position is injected intraperitoneally in experimental rat.
(2) skin is cut perpendicular to line away from external auditory canal line midpoint in left eye outer canthus.
(3) combine before cheekbone and squamosal bone and open cranium, surgical operation microscope incision with self-control diameter 2mm drill bit punching at 2mm Open endocranium, exposure arteria cerebri media initial part.
(4) arteria cerebri media initial part is burnt with electric heater.
(5) more relatively fixed, make blood clotting, complete blocking blood flow.
(6) hemostasis is gently pressed with gelfoam if meeting angiorrhoxis and causing bleeding, the cemented pulvis of bone window trbasic zinc phosphate is solid Envelope, layer-by-layer suture subcutaneous tissue and skin.
[observation index]
(1) Symptom Observation: rat contralateral limbs are powerless, and when walking obviously rotates to opposite side, before being unable to full extension opposite side Limb mentions body when tail stands upside down and bends towards opposite side, and forelimb is sagging.
And neurological deficit score is carried out according to Hunter standard:
1. 0 point: impassivity injury symptoms；
2. 1 point: being unable to full extension opposite side forelimb；
3. 2 points: turn-taking to paralysis side；
4. 3 points: toppling over to opposite side；
5. 4 points: being unable to automatically walk, the loss of consciousness.
(2) brain edema measures: brain cortex tissue is quickly taken after putting to death animal, it is aqueous using dry and wet weight method measurement brain tissue Amount.
(3) Brain stem injury is observed: quickly being taken cerebral tissue after putting to death animal, is sliced, is put into after freezing 20min In 2% triphenyltetrazolium chloride (TTC) solution that 0.2mol/L phosphate buffer (PBS) is configured to, 37 DEG C of dyeing 50min, Observe and measure Brain stem injury.It is in bluish violet after the dyeing of rat normal cerebral tissue, infarcted region is white.
(4) the horizontal measurement of serum superoxide dismutases (SOD), malonaldehyde (MDA): polarography determination SOD in serum is used Activity measures MDA using spectrophotometry.
[experimental method]
(1) from modeling successful rat 60 similar in selective body weight, 6 groups, i.e. blank pair experimental group: are randomly divided into According to group (not medication), positive drug group (Xueshuan xinmaining Tablet), test medicine group (embodiment 1), (comparison of control drug 1-3 group Example 1-3).
(2) medication: oral administration gavage administration, positive drug, test medicine and control drug are according to 800mg/kgd Weight administration, after weighing in daily morning and evening, gives the suspension of relative medicine respectively, and successive administration 60 days.
[experimental result]
Living animal observation index
Clinical observation: including but is not limited to death condition, the state of mind, behavioral activity, morbidity, breathing, secretion, excrement Just, diet, drinking-water situation and skin, coat, eyes, ear, nose, abdomen, external genital organs, anus, four limbs and foot etc..
Weight: all animals measure weight with before being grouped after the receipt, and measure weight before the dying euthanasia of animal.
Successive administration puts to death animal after 60 days, carry out Indexs measure.Testing result is as shown in table 1 below:
1 groups of animals testing result of table
Note: compared with blank control group:*P≤0.05；**P≤0.01.
From table 1 it follows that compared with blank control group, at the end of experiment, the neurological deficit score of each group rat, brain group Knit water content, Brain stem injury and SOD in serum, serum MDA level has different degrees of improvement, prompt each group rat cerebral infarction institute The cerebral ischemia degree of cause is mitigated.In comparison, the therapeutic effect of pharmaceutical composition (embodiment 1) of the present invention is better than sun Property drug and each comparative example group pharmaceutical composition, without Distylium racemosum leaf extract and brown in 1 group of pharmaceutical composition composition formula of comparative example Spot Buddhist temple powder is free of Distylium racemosum leaf extract, 3 groups of pharmaceutical composition composition formulas of comparative example in 2 groups of pharmaceutical composition composition formulas of comparative example In be free of Kalanchoe Tomentosa powder, curative effect is not satisfactory, thus explanation in the formula of this pharmaceutical composition, Distylium racemosum leaf extract Object and Kalanchoe Tomentosa powder play fundamental role, and certain cooperate with can be generated between above two ingredient and other raw materials Effect facilitates the every symptom and index that improve cerebral infarction rat model convalescence.
The preferred embodiments of the disclosure and embodiment are explained in detail above, but the present invention is not limited to The above-described embodiment and examples can also not depart from the present invention within the knowledge of those skilled in the art Various changes can be made under the premise of design.

Claims (10)

1. a kind of pharmaceutical composition for treating cerebral infarction, it is characterised in that it is made of the raw material of following weight parts:
False portulaca oleracea extracts 300-450, Distylium racemosum leaf extract 300-325,
Kalanchoe Tomentosa powder 120-130, citicoline 470-510,
Nattokinase 90-105, vinpocetine 9-12.
2. the pharmaceutical composition for the treatment of cerebral infarction as described in claim 1, false portulaca oleracea extracts are under described in raw material It states method to be made: measuring 30% ethyl alcohol for being added 8-10 times after bacopa monnieri rinsing, dry, crushing, refluxing extraction after impregnating 2 hours 1 hour, medical fluid filtration, filtrate was spare, repeated to extract 1 time by filter residue under the same conditions, filtering, and merging filtrate is concentrated under reduced pressure It is spray-dried after to small size, obtains false portulaca oleracea extracts.
3. the pharmaceutical composition for the treatment of cerebral infarction as described in claim 1, Distylium racemosum leaf extract described in raw material is under It states method to be made: Distylium racemosum leaf being rinsed, is dry, is crushed to 5 times of amount petroleum ethers of addition after 200 mesh, vacuum is taken out after impregnating 2 hours Filter, discards filtrate, and 8-10 times is added into filter residue and measures Yi Chun ﹕ ethyl acetate=7 ﹕, 3 mixed solution, flows back and mentions after impregnating 1 hour It takes 1 hour, medical fluid filtration, filtrate is spare, repeats to extract 1 time by filter residue under the same conditions, and filtering merges filtrate twice, subtracts Pressure is spray-dried after being concentrated into small size, obtains Distylium racemosum leaf extract.
4. the pharmaceutical composition for the treatment of cerebral infarction as described in claim 1, Kalanchoe Tomentosa powder described in raw material is according to following sides Method is made: by Kalanchoe Tomentosa blade rinsed clean, 80-90 DEG C is dried, and 300-400 mesh is crossed after ultramicro grinding, obtains foxiness gal Blue powder.
5. the pharmaceutical composition for the treatment of cerebral infarction as described in claim 1, it is characterised in that described pharmaceutical composition is by following Step is made:
(1) 8-10 times being added after bacopa monnieri rinsing, dry, crushing and measuring 30% ethyl alcohol, refluxing extraction 1 is small after impregnating 2 hours When, medical fluid filtration, filtrate is spare, repeats to extract 1 time by filter residue under the same conditions, and filtering, merging filtrate is concentrated under reduced pressure into small It is spray-dried after volume, obtains false portulaca oleracea extracts；
(2) Distylium racemosum leaf rinsed, be dry, being crushed to 5 times of amount petroleum ethers of addition after 200 mesh, be filtered by vacuum after impregnating 2 hours, Filtrate is discarded, 8-10 times is added into filter residue and measures Yi Chun ﹕ ethyl acetate=7 ﹕, 3 mixed solution, refluxing extraction 1 after impregnating 1 hour Hour, medical fluid filtration, filtrate is spare, repeats to extract 1 time by filter residue under the same conditions, and filtering merges filtrate twice, depressurizes dense It is spray-dried after being reduced to small size, obtains Distylium racemosum leaf extract；
(3) by Kalanchoe Tomentosa blade rinsed clean, 80-90 DEG C is dried, and 300-400 mesh is crossed after ultramicro grinding, obtains foxiness gal Blue powder；
(4) by above-mentioned false portulaca oleracea extracts, Distylium racemosum leaf extract, Kalanchoe Tomentosa powder and citicoline, Nattokinase, length Chun Xiting mixing, mixes well in blender to get this pharmaceutical composition.
6. the pharmaceutical composition for the treatment of cerebral infarction as described in claim 1, wherein the parts by weight of each raw material are:
False portulaca oleracea extracts 300, Distylium racemosum leaf extract 300,
Kalanchoe Tomentosa powder 120, citicoline 470,
Nattokinase 90, vinpocetine 9.
7. the pharmaceutical composition for the treatment of cerebral infarction as described in claim 1, wherein the parts by weight of each raw material are:
False portulaca oleracea extracts 360, Distylium racemosum leaf extract 310,
Kalanchoe Tomentosa powder 125, citicoline 500,
Nattokinase 100, vinpocetine 10.
8. the pharmaceutical composition for the treatment of cerebral infarction as described in claim 1, wherein the parts by weight of each raw material are:
False portulaca oleracea extracts 450, Distylium racemosum leaf extract 325,
Kalanchoe Tomentosa powder 130, citicoline 510,
Nattokinase 105, vinpocetine 12.
9. such as the pharmaceutical composition of the described in any item treatment cerebral infarctions of claim 1-8, it is characterised in that described pharmaceutical composition By the method for preparing tablet, capsule, pill, granule, powder or suspension of this field routine, this drug is further made Composition tablet, capsule, pill, granule, powder or suspension.
10. if the pharmaceutical composition of the described in any item treatment cerebral infarctions of claim 1-8 is in preparation treatment cerebral apoplexy drug Using.
CN201811324080.0A 2018-11-08 2018-11-08 A kind of pharmaceutical composition for treating cerebral infarction Pending CN109289043A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811324080.0A CN109289043A (en) 2018-11-08 2018-11-08 A kind of pharmaceutical composition for treating cerebral infarction

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201811324080.0A CN109289043A (en) 2018-11-08 2018-11-08 A kind of pharmaceutical composition for treating cerebral infarction

Publications (1)

Publication Number Publication Date
CN109289043A true CN109289043A (en) 2019-02-01

Family

ID=65145357

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201811324080.0A Pending CN109289043A (en) 2018-11-08 2018-11-08 A kind of pharmaceutical composition for treating cerebral infarction

Country Status (1)

Country Link
CN (1) CN109289043A (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103055007A (en) * 2012-11-16 2013-04-24 中国人民解放军第二军医大学 Application of total saponins of bacopa monnieri (L.) wettst. in preparation of medicaments for resisting cerebral ischemia
CN104546883A (en) * 2014-12-31 2015-04-29 广东药学院 Preparation and application of flavonol as brain-targeting synergist

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103055007A (en) * 2012-11-16 2013-04-24 中国人民解放军第二军医大学 Application of total saponins of bacopa monnieri (L.) wettst. in preparation of medicaments for resisting cerebral ischemia
CN104546883A (en) * 2014-12-31 2015-04-29 广东药学院 Preparation and application of flavonol as brain-targeting synergist

Similar Documents

Publication Publication Date Title
CN108567910A (en) The Chinese medicine composition of eye strain is alleviated in a kind of external application
RU2322997C2 (en) Injection composition prepared from ixeris sonchifolia hance for treatment of cardio- and cerebrovascular diseases and fundus of eye diseases and method for its preparing
CN102813780A (en) Chinese herbal medicinal compound preparation used for treating macular degeneration of old people and preparation method thereof
CN101780227B (en) Traditional Chinese medicine composition for treating acute stroke and preparation method thereof
CN108186639B (en) A kind of pharmaceutical composition of SS 717
CN109289043A (en) A kind of pharmaceutical composition for treating cerebral infarction
CN105769754A (en) Metronidazole gel free of preservative and preparation method thereof
CN102078509B (en) Traditional Chinese medicine preparation for treating ophthalmorrhagia and preparation method thereof
CN105920280B (en) A kind of compound preparation and preparation method thereof for treating retinopathy and amblyopia
CN106860509A (en) The production technology of carpet bugle capsule
CN101167733A (en) Venous injection powder injection for preventing and treating ischemic cerebral apoplexy and preparation method thereof
CN105395436A (en) Acne cream and preparation method thereof
CN100446775C (en) Chonsurid for venous injection administration and its preparing method
CN104306546A (en) A traditional Chinese medicine composition used for treating optic atrophy, and decoctions, pills and powder of the composition
CN109394838B (en) Pharmaceutical composition for treating age-related macular degeneration
CN108042552A (en) A kind of pharmaceutical composition containing Aescinate B
CN108553596A (en) One kind can composition for relieving asthenopia and preparation method and application
CN107865875A (en) A kind of pharmaceutical composition containing Aescinate A
CN102764437B (en) Methoxsalen injection and preparation method thereof
CN106581445A (en) Traditional Chinese medicine prescription for treating diabetic retinopathy
CN105535056A (en) Traditional Chinese medicine preparation for treating viral meningitis and preparation method and application thereof
CN105963498A (en) Traditional Chinese medicinal composition used for postoperative rehabilitation and preparation method thereof
CN104825809A (en) Medicament for treating peripheral facial paralysis
CN105288016B (en) External traditional Chinese medicine emulsion for preventing and treating knee osteoarthritis and preparation method thereof
CN103479845B (en) Method for preparing freeze-dried powder injection promoting estrogen secretion from aloes and pseudo-ginseng

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20190201

RJ01 Rejection of invention patent application after publication